NIAID Emerging and Re-emerging Infectious Diseases NIAID Bioinformatics Resource Centers NIAID Structural Genomic Centers Center for Structural Genomics of Infectious Disease
Seattle Structural Genomics Center for Infectious Disease

MyleA.00213.a: Putative enoyl-CoA hydratase

Target Characteristics

from organism: Mycobacterium leprae Br4923
most recent status: selected
center reference id: MyleA.00213.a
is community request: False
associated disease: Hansen's disease, leprosy
NIH risk group: 2
is select agent: False
NIH priority
pathogens category:
IIIC

Ordering Clones & Proteins

If there are materials available for this target, they will be listed below. Materials can be ordered from SSGCID using the button in the "order material" column. Clicking the button will add the material to a virtual cart. You may order multiple materials at a time at no cost to you, as this contract is funded by NIAID. When you are ready to place your order, click the "Place Order" link which will appear in the top right corner of the page after you place your first item in your cart.

External Resources

Resource Reference ID
OrthoMCL: OG5_129459
PATRIC ID: fig|561304.4.peg.181
RefSeq: YP_002502847.1
UniProt: A0A0H3MP13

Enzyme & Pathway Information

Pathway Pathway ID EC Number
fatty acid beta-oxidation I FAO-PWY 4.2.1.17
L-isoleucine degradation I ILEUDEG-PWY 4.2.1.17
oleate beta-oxidation PWY0-1337 4.2.1.17
phenylacetate degradation I (aerobic) PWY0-321 4.2.1.17
benzoyl-CoA degradation I (aerobic) PWY-1361 4.2.1.17
fermentation to 2-methylbutanoate PWY-5109 4.2.1.17
fatty acid beta-oxidation II (peroxisome) PWY-5136 4.2.1.17
unsaturated, even numbered fatty acid beta-oxidation PWY-5138 4.2.1.17
superpathway of glyoxylate cycle and fatty acid degradation PWY-561 4.2.1.17
superpathway of phenylethylamine degradation PWY-6071 4.2.1.17
4-hydroxybenzoate biosynthesis III (plants) PWY-6435 4.2.1.17
fatty acid beta-oxidation VI (peroxisome) PWY66-391 4.2.1.17
pyruvate fermentation to hexanol (engineered) PWY-6863 4.2.1.17
superpathway of cholesterol degradation I (cholesterol oxidase) PWY-6928 4.2.1.17
superpathway of testosterone and androsterone degradation PWY-6937 4.2.1.17
androstenedione degradation PWY-6944 4.2.1.17
superpathway of cholesterol degradation II (cholesterol dehydrogenase) PWY-6947 4.2.1.17
methyl ketone biosynthesis (engineered) PWY-7007 4.2.1.17
4-coumarate degradation (anaerobic) PWY-7046 4.2.1.17
fatty acid salvage PWY-7094 4.2.1.17
jasmonic acid biosynthesis PWY-735 4.2.1.17
docosahexaenoate biosynthesis III (6-desaturase, mammals) PWY-7606 4.2.1.17
(8E,10E)-dodeca-8,10-dienol biosynthesis PWY-7654 4.2.1.17
Spodoptera littoralis pheromone biosynthesis PWY-7656 4.2.1.17
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate biosynthesis (6-desaturase) PWY-7726 4.2.1.17
toluene degradation to benzoyl-CoA (anaerobic) PWY-81 4.2.1.17
L-valine degradation I VALDEG-PWY 4.2.1.17

Sequences

These sequences are the native gene sequence; sequences of constructs derived from these sequences may differ due to codon optimization or other protocols. To find the specific sequence of any material you may have ordered, click on the "more" button next to the name of that material.
AA Sequence
MGSDINRAYE SVAVEIKDRV AQVTLIGPGK GNAMGPAFWS EMPEVFAELD TNREVRAVVI TGSGKDFSYG LDVPAMGGKF VPLLTDGALA RPRTDFHAEV LRMQKAINAV ADCRTPTIAA VHGWCIGGAL DLISAVDIRY ASADAKFSMR EVKLAIVADM GSLARLPLIL SDGHLRELAL TGKDIDATRA EKIGLVNDVY DNADKTLAAA HATAAEIAAN PPLAVYGVKD VLYQQRTSAI SESLRYVAAW NAAFLPSKDL TEGISATFAK RAPQFIGE

NT Sequence
ATGGGCTCAG ACATAAATCG GGCATATGAA TCCGTTGCCG TCGAAATCAA AGATCGGGTT GCACAGGTAA CACTGATCGG GCCAGGCAAG GGCAACGCGA TGGGGCCGGC CTTCTGGTCG GAGATGCCGG AGGTGTTCGC AGAGCTAGAT ACCAACCGTG AGGTACGGGC CGTCGTCATC ACCGGATCAG GAAAAGATTT TAGCTACGGC CTGGACGTGC CCGCGATGGG CGGAAAGTTC GTCCCATTGC TGACCGACGG CGCACTGGCA CGCCCCCGCA CCGACTTCCA CGCCGAAGTG CTGCGGATGC AGAAGGCGAT AAACGCCGTC GCTGATTGCC GCACGCCCAC GATCGCGGCG GTGCACGGCT GGTGCATTGG TGGCGCTTTA GACCTGATCT CCGCGGTCGA TATCCGCTAC GCCAGCGCCG ACGCCAAGTT CTCAATGCGG GAAGTCAAAC TGGCCATAGT CGCCGACATG GGCAGTCTCG CCCGCCTTCC ACTGATCTTG AGCGACGGGC ATCTGCGTGA ACTGGCGTTG ACGGGAAAAG ACATCGACGC GACCCGCGCC GAGAAAATTG GCCTTGTAAA TGATGTCTAC GACAATGCCG ACAAGACGCT GGCTGCCGCC CATGCCACCG CTGCCGAGAT CGCCGCCAAC CCGCCACTAG CGGTCTACGG CGTCAAGGAT GTCCTTTACC AACAACGCAC CTCCGCGATC TCAGAGAGCC TACGCTACGT CGCTGCGTGG AACGCGGCCT TTCTGCCGTC CAAGGATCTG ACCGAGGGCA TATCGGCCAC GTTCGCCAAG CGGGCACCGC AGTTCATCGG GGAG

© 2022 Seattle Children's Research Institute. All rights reserved.